ATRC

Over the past six months, AtriCure's stock was influenced by several events. The company reported strong Q2 2026 financial results on July 23, 2026, with worldwide revenue up 12.8% year-over-year to $153.6 million, and improved profitability with a net income of $9.0 million and adjusted EBITDA of $27.3 million, leading to raised full-year 2026 revenue guidance to $600 million-$610 million. The stock surged approximately 26% in the 30 days leading up to late September 2026, more than doubling over the quarter to around $61. This rally was supported by ATRC's addition to the S&P 1000 index in September 2026 and the Society of Thoracic Surgeons (STS) incorporating concomitant Afib treatment as a quality metric. After reaching a new 52-week high of $61.70, the stock experienced an 8.2% pullback in early October 2026. On October 2, 2026, Freedom Capital downgraded AtriCure to 'Hold' from 'Buy' but raised the price target to $57 from $43, noting that mid-term growth acceleration was largely priced in. Insider selling under 10b5-1 plans, including by the Chief Technical Officer, was reported in September 2026. The company also participated in several healthcare conferences, including those hosted by Wells Fargo, Canaccord Genuity, Goldman Sachs, and Bank of America Securities.